James Symanowski

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Ejection Fraction

Top Venues

JCO precision oncology

JCO oncology practice

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

D Grace Nguyen, Sarah A Morris, Alicia Hamilton, Simeon O Kwange, Nury Steuerwald, James Symanowski, Donald C Moore, Sarah Hanson, Kaitlyn Mroz, Karine E Lopes, Chris Larck, Laura Musselwhite, Kunal C Kadakia, Brinda Koya, Seungjean Chai, Kwabena Osei-Boateng, Sini Kalapurakal, Kristen Swift, Jimmy Hwang, Jai Narendra Patel
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase ( DPYD ) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center. JCO precision oncology 8 (2024)
D Grace Nguyen, Sarah A Morris, Alicia Hamilton, Simeon O Kwange, Nury Steuerwald, James Symanowski, Donald C Moore, Sarah Hanson, Kaitlyn Mroz, Karine E Lopes, Chris Larck, Laura Musselwhite, Kunal C Kadakia, Brinda Koya, Seungjean Chai, Kwabena Osei-Boateng, Sini Kalapurakal, Kristen Swift, Jimmy Hwang, Jai Narendra Patel
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase ( DPYD ) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center. JCO precision oncology 8 (2024)
Carol J Farhangfar, Gregory T Scarola, Victoria A Morris, Farhang Farhangfar, Kathryn Dumas, James Symanowski, Jimmy J Hwang, Kathryn F Mileham, Daniel R Carrizosa, R Wendel Naumann, Chad Livasy, Edward S Kim, Derek Raghavan
Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients. JCO clinical cancer informatics 6 (2022)
Thomas G Knight, Melissa Aguiar, Myra M Robinson, Allison Morse, Tommy Chen, Rupali Bose, Jing Ai, Brittany Knick Ragon, Aleksander L Chojecki, Nilay A Shah, Srinivasa R Sanikommu, James Symanowski, Edward A Copelan, Michael R Grunwald
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy. JCO oncology practice 18 (9) (2022)